ArticleImmunoTargets and therapy2025

PD-L1/ITGB4 Axis Modulates Sensitivity of Hepatocellular Carcinoma to Sorafenib via FAK/AKT/mTOR Signaling Pathway.

Tao Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.